Form 8-K Sarepta Therapeutics, For: Sep 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Sarepta Therapeutics (SRPT) Appoints Edward Kaye as Permanent CEO; Updates on Exec Team
September 21, 2016 8:41 AM EDTSarepta Therapeutics (Nasdaq: SRPT) disclosed the following in a U.S. SEC filing on Wednesday morning:
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On September 20, 2016, the Board of Directors (the Board) of Sarepta Therapeutics, Inc. (the Company) appointed Edward M. Kaye, M.D. as President and Chief Executive Officer (CEO) of the Company and to serve as a member of the Board. Dr. Kaye will continue in his role as Chief Medical Officer, a role which he has held since June 2011. Prior to his new... More
